



Allopurinol (ALLO) is a urate-lowering active pharmaceutical ingredient (API) that acts by decreasing the formation of uric acid through the 
inhibition of xanthine oxidase and is included in the World 
Health Organization (WHO) List of Essential Medicines 
(1). The drug was first approved by the United States 
Food and Drug Administration (US FDA) in 1966, and is 
currently used worldwide for the treatment of gout, 
gouty arthritis, uric acid stones, or hyperuricemia due to 
cancer or chemotherapy (2, 3). In fact, the development 
of ALLO was one of the most important advances in the 
treatment of hyperuricemia, an effort that was awarded 
with the 1988 Nobel Prize in medicine (4, 5).   
ALLO presents a solubility value in water and 25 °C of 0.48 
mg/mL. (6). This API is presented in the pharmaceutical 
market at two dosage strengths, 100 and 300 mg. The 
100-mg formulation is one example of APIs now included 
in the class 1 of the Biopharmaceutics Classification 
System (BCS) (7). Before the change in WHO regulations, 
where the permeability criterion was relaxed from the 
FDA value of 90% to 85% to consider an API as ‘highly 
permeable’, the ALLO classification included mostly BCS 
class 3, and eventually a class 4 case (8–10). Classification 
of the 300-mg formulation of ALLO is not straightforward, 
but the FDA clearly indicates that ALLO 300 mg belongs to 
class IV (11).
In Argentina, ALLO tablets are available both as a 
reference and multisource product. In the Argentinean 
pharmaceutical market, it is a common practice for 
patients to replace the reference with multisource 
products, and even between the latter ones, based 
on economic reasons. Even though treatments could 
become more effective if patients were provided 
with proper knowledge to comprehend their care, it is 
important to point out that multisource products must 
have proven pharmaceutical equivalence. To establish 
that products containing the same API are pharmaceutical 
equivalents (i.e., same quantity, dosage form, and 
route of administration), it must be verified that they 
all comply with comparable critical quality standards 
(12, 13). Furthermore, in vitro dissolution studies can 
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be applied to obtain useful information concerning the 
biopharmaceutical performance of the products. In this 
sense, dissolution profiles can be obtained in dissolution 
media of biological relevance, such as aqueous buffer 
solutions with pH values in the physiological range. In the 
case of APIs belonging to BCS class 1 and 3, this procedure 
corresponds to similarity studies (for biowaivers), which 
are used to assess interchangeability of formulations in 
lieu of in vivo studies, under recommendations of national 
and international regulatory agencies (13–17). In the 
case of APIs outside this classification, the assessment of 
dissolution behavior in media of physiological relevance 
completes the critical evaluation of pharmaceutical 
equivalence and assures the availability of essential drugs 
of proven quality, safety, and efficacy at affordable prices.
To the best of our knowledge, only one study has been 
published in the literature comparing different ALLO 
products, and there are no studies regarding products 
marketed in Argentina (18). Therefore, the aim of the 
present study was to assess critical quality attributes and 
pharmaceutical equivalence of five commercial products 
containing ALLO (300 mg), marketed in Argentina, with 
focus on their biopharmaceutical performance. 
MATERIALS AND METHODS
Materials
ALLO was acquired from Saporiti (Parafarm, Argentina). 
Distilled water was used for assay and preparation of 
dissolution media. Analytical grade chemicals were used 
for the same purpose, namely sodium hydroxide (NaOH), 
hydrochloric acid (HCl), glacial acetic acid, potassium 
chloride, sodium acetate trihydrate and monobasic 
potassium phosphate (ANEDRA, Argentina). Aqueous 
buffer solutions (pH 1.2 HCl, pH 4.5 acetate, and pH 6.8 
phosphate), used as dissolution media of physiological 
significance, were prepared in compliance with the 
United States Pharmacopeia (USP) (19).
Five different ALLO tablets (labeled amount: 300 mg) were 
purchased in local pharmacies of the Argentine market. 
Tablets were arbitrarily labeled from A to E, with sample D 
being the reference product, and the other formulations 
being multisource products. The composition of the 
evaluated formulations is presented in Table 1. All tests 
were performed within the shelf life of the products. 
The information present in labels (primary and secondary 
packaging) and patient leaflets was evaluated and 
compared  to  verify compliance  with local legislation 
(20, 21).
Equipment 
A Varian Cary 50 Conc Spectrophotometer (Varian 
Instruments, Australia) was used for assay and 
quantification of API in dissolution studies. Hardness, 
friability, and disintegration of the tablets were measured 
using a Scout DGM02, FGMO2, and EGMO2, respectively 
(Scout Electronics, Argentina). In vitro dissolution studies 
were performed with an Erweka DT60 (Erweka GmbH, 
Germany). An Acculab ALC- 210.4M (Acculab, USA) 
electronic analytical balance was used to weigh materials 
and tablets. 
Evaluation of Critical Quality Attributes
For weight variation analysis, 10 randomly chosen tablets 
from each commercial sample were individually weighed, 
and the mean value and corresponding standard deviation 
(SD) were calculated.
Friability, hardness, and disintegration tests were 
completed according to Argentine Pharmacopeia (20). 
Ten tablets from each sample were weighed and placed 
into the friability tester. After 100 revolutions (25 rpm for 




Excipient Ab B Cc D 
(Ref.)
Ec
Filler/Diluent Lactose – + + –
Microcrystalline 
Cellulosea + – – +
Disintegrant Corn Starcha – + + –
Povidonea + + + +
Crospovidone – – – –
Croscarmellose 
sodium – + + +
Docusate Sodiuma – – – –
Sodium Starch 
Glycolate + – – –
Pregelatinized 
starcha – – + –
Glidant Sodium Lauryl 
Sulphatea – – – –
Colloidal Silicon 
Dioxide + – + +
Talca – – – –
Lubricant Magnesium 
Stearate + + + +
Polyethylene glycol – – – +
aThis excipient has multiple functions.
bLabel and/or leaflet do not inform qualitative composition of excipients.
cLabel and/or leaflet inform qualitative and quantitative composition of 
excipients.
+ indicates presence and – indicates absence of excipient. 
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4 min), the tablets were removed from the tester and 
weighed, and the result was compared with the initial 
weight value (20). The hardness of 10 individual tablets 
of each sample was measured in terms of the degree of 
force in kilopounds (kp) required to break each tablet 
across the diameter. The disintegration time of tablets 
(n = 6, for each sample) was assessed at 37.0 ± 2.0 °C in 
distilled water for 30 minutes. Unless otherwise specified 
in the corresponding monograph, it should be observed 
that all tablets completely disintegrate in the indicated 
testing time (20).
For the assay test, 20 tablets were randomly selected, 
weighed, and finely powdered. An exactly weighed 
quantity of powder, containing approximately 100 mg of 
ALLO, was dissolved using 0.05 M NaOH. The obtained 
solution was filtered through a 0.45-μm pore-size nylon 
membrane (Gamafil, Argentina) and suitably diluted with 
0.1 M HCl. ALLO concentration was determined by UV-
spectrophotometry at 250 nm (applying the standard 
calibration curve developed for this purpose: y = 0.0576 
x – 0.0096; r2=0.9998; concentration range 4.0–14.0 µg/
mL) (22, 23). This same methodology was individually 
applied to 10 tablets of each commercial sample for 
assessment of uniformity of dosage units. 
Dissolution tests were performed using a calibrated USP 
apparatus 2 at 75 rpm with 900 mL of 0.01 N HCl at 37.0 
± 0.5 °C as dissolution medium (19, 20). Six replicates (n 
= 6) of each product were evaluated for stage 1 (S1) of 
dissolution acceptance criteria. Samples were withdrawn 
at the time specified in the corresponding monograph 
(45 min), filtered through a 0.45-μm pore-size nylon 
membrane (Gamafil), and suitably diluted with the 
same medium. Drug concentration was determined by 
spectrophotometric analysis at 250 nm (applying the 
following calibration curve: y = 0.0584 x – 0.0249; r2 = 
0.9997). Argentine Pharmacopeia states that not less 
than 75% (Q) of the labeled amount of ALLO should be 
dissolved within 45 minutes (20).
Biopharmaceutical Performance of ALLO tablets  
To evaluate the biopharmaceutical performance of the 
selected products, dissolution profiles (n = 12 for each 
sample) were performed at pH 1.2, 4.5, and 6.8, applying 
the same experimental conditions of the dissolution 
quality control test (as stated above). Samples (10 mL) were 
withdrawn at 5, 10, 15, 20, 30, 45, and 60 minutes (with 
replacement of fresh medium) and subsequently filtered, 
diluted, and measured by UV analysis. The concentration 
in each sample was calculated from calibration curves 
constructed in each dissolution medium (r2 range: 
0.9973–0.9994). Cumulative percentages of dissolved API 
were calculated for dissolution profile assessment, where 
each point of the dissolution profile corresponds to the 
mean value and its respective SD. 
Statistical Analysis 
Dissolution profiles were characterized in terms of the 
model independent parameter dissolution efficiency 
(DE) (24). DE values were statistically evaluated applying 
analysis of variance (ANOVA) followed by least significant 
difference (LSD). Mathematical comparison of dissolution 
profiles was carried out in terms of similarity factor, f2 
(13–17). Statistical analysis was performed using InfoStat 
software, version 2014 (http://www.infostat.com.ar).
RESULTS AND DISCUSSION 
Not all the evaluated products could be considered 
equivalent with respect to the information provided about 
storage conditions (Table 2). Argentine Pharmacopeia 
states that the correct storage conditions should be 
"to preserve in well-closed containers,” and this should 
be indicated both in the secondary packaging and 
patient leaflet (20). None of the samples indicated the 
requirement of “well-closed” packaging, although sample 
C indicated keeping the tablets in their original container. 
All samples referred to conditions of appropriate 
storage, and almost all presented an upper limit of 30 
°C. Concerning the general information provided by the 
manufacturers, it is important to highlight that sample 
A did not provide information about the composition of 
excipients (qualitative not quantitative ) (Table 1), which 
is a requirement of local legislation (21). Another issue is 
the important differences in the prices of evaluated ALLO 
products, with sample E having the highest cost, 62.5% 
higher than the most economic one (sample A) (Table 
2). This is an important factor to be considered because 
interchangeability decisions by patients in Argentina are 
generally based on economic reasons.
Critical Quality Attributes  
The results of physical tests are shown in Table 2. Large 
differences were detected between the weight values 
of different samples, with mean results ranging from 
432.0 to 720.2 mg. Differences in composition, typical 
of each manufacturer (and presented in Table 1), and 
different physical dimensions of each product could 
explain this range of results, without necessarily involving 
variations in the API content or dissolution performance. 
With respect to hardness evaluation, the mean results 
ranged from 7.5 to 34.3 kp, which could be considered 
an acceptable range. In the case of friability tests, the 
pharmacopeial specification states that ‘a maximum 
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mean weight loss of not more than 1.0% is considered 
acceptable’ (19, 20). All evaluated samples fulfilled this 
requirement, as shown in Table 2. For disintegration 
assessment, the pharmacopeial specification states that 
‘at the end of the time limit specified in the monograph 
all of the tablets have disintegrated completely’ (19, 20). 
All evaluated products showed acceptable disintegration 
times, with results ranging between 51 seconds and 
almost 6 minutes (Table 2). Therefore, all samples met 
the official compendium requirement of 30-minute 
disintegration time (20). It is important to point out 
that the hardest formulation (sample E) also exhibits 
the lowest weight loss in friability determination and 
the longest disintegration time (Table 2). Nevertheless, 
no apparent relationship could be found, because the 
sample with the lowest hardness value (sample B) had an 
intermediate result for friability and disintegration time, 
and samples with similar friability and disintegration time 
(samples E and C) differed in hardness results (Table 2). 
ALLO tablets should contain an amount equivalent to 
93.0–107.0 % of the labeled amount of ALLO, as indicated 
in the respective monograph (20). As shown in Table 3, 
assay results for all evaluated products fulfilled these 
requirements, with results that ranged from 97.8 ± 2.6 
(sample A) to 103.7 ± 2.1 (sample E). On the other hand, 
the specifications for uniformity indicate that API content 
should be between 85.0–115.0% of the labeled amount 
in each evaluated dosage unit, and the relative standard 
deviation (RSD) should not exceed 6.0% (20). All evaluated 
products fulfilled these requirements. 
The ALLO tablets monograph includes specifications for 
in vitro dissolution testing, stating that ‘not less than 
75% (Q) of the labeled amount of ALLO is dissolved in 45 
minutes’ (20). According to the results shown in Table 3, 
all formulations complied with specification for the S1 
dissolution test. 
Table 3. Assay, Uniformity of Dosage Units, and Dissolution Test 
Results for Allopurinol Formulations 
Sample






75% (Q) in 45 min
A 97.8 ± 2.6 95.9–100.0 / 1.2 88–92 / 1.8
B 101.5 ± 2.9 100.5–102.8 / 0.8 89–92 / 1.7
C 99.2 ± 2.0 98.8–100.3 / 0.5 90–95 / 2.4
D (Ref.) 102.1 ± 2.8 100.3–104.2 / 1.2 101–105 / 2.0
E 103.7 ± 2.1 102.5–105.7 / 1.0 100–102 / 1.1
�Percentage of labeled amount. Mean value ± SD.
�Range of % labeled amount / RSD.
�Range of % labeled amount dissolved /RSD. S1 Stage corresponds to the 
first (of three) instance of approval for in vitro dissolution test according 
to the acceptance table for “Dissolution” chapter in United States 
Pharmacopeia.
RSD: relative standard deviation; Q: amount of dissolved active 
pharmaceutical ingredient, specified in the individual monograph, 
expressed as a percentage of labeled content of the dosage unit.
Biopharmaceutical Performance  
Dissolution profiles obtained in physiologically relevant 
media are presented in Figures 1–3. The reference 
formulation (D) and the samples B and E are considered 
as ‘very rapidly dissolving’ (i.e., 85% dissolved in the first 
15 minutes). On the other hand, DE results could be 
considered satisfactory, because values were greater 
than 77.0% for all samples and all media, with the 
highest values registered for samples D and E (Table 4). 
Table 2. Information of Evaluated Products and Results of Physical Quality Control Tests for Allopurinol Formulations 
Sample Pricea Storage Conditionsb Tablet Weight 
(mg)c




A 3.46 Store between 15 and 30 °C 432.0 ± 5.0 9.7 ± 0.5 0.41 51 s
B 4.86 Store at a room temperature 
(pref. between 15 and 30 °C).
451.3 ± 3.7 7.5 ± 0.3 0.29 2 min 36 s
C 5.30 Store at a room temperature 
between 15 and 30 °C, in its 
original case and protected 
from light and heat.
695.7 ± 3.0 11.6 ± 0.5 0.04 5 min 36 s
D (Ref.) 5.34 Store in original case at room 
temperature and dry place.
708.9 ± 7.0 15.8 ± 1.0 0.05 5 min 11 s
E 5.62 Store at room temperature 
be-low 30 °C.
720.2 ± 7.0 34.3 ± 0.1 0.04 5 min 42 s
�Price per tablet in argentine pesos at the time of analysis. 
�Information presented in labels and leaflets.
�Mean value ± SD.
�Maximum time needed for complete disintegration of evaluated tablets. 
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Figure 1. Dissolution profiles for Allopurinol formulations in hydrochloric buffer solution (pH 1.2).  Each point of the profile represents the mean 
result for the percentage of ALLO labeled amount dissolved, at each sampling time, and the corresponding error bars (standard deviation). 
Dotted lines represent the ‘very rapidly dissolving’ limits (85% dissolved at 15 minutes).
Figure 2. Dissolution profiles for Allopurinol formulations in acetic buffer solution (pH 4.5).  Each point of the profile represents the mean result 
for the percentage of ALLO labeled amount dissolved, at each sampling time, and the corresponding error bars (standard deviation). Dotted 
lines represent the ‘very rapidly dissolving’ limits (85% dissolved at 15 minutes).
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Figure 3. Dissolution profiles for Allopurinol formulations in phosphate buffer solution (pH 6.8).  Each point of the profile represents the mean 
result for the percentage of ALLO labeled amount dissolved, at each sampling time, and the corresponding error bars (standard deviation). 
Dotted lines represent the ‘very rapidly dissolving’ limits (85% dissolved at 15 minutes).
The statistical comparison of these results (by ANOVA) 
revealed the existence of significant differences in DE 
results for samples A and C, with respect to the reference 
formulation, in all media (Table 4). In the case of sample 
B, significant differences were detected in pH 1.2 and 
4.5 buffer solutions, but not in phosphate buffer (Table 
4). Finally, for sample E no statistical differences were 
detected when compared to reference formulation, in all 
media (Table 4). Dissolution profiles were also compared 
using the similarity factor, f2. Even though 300-mg ALLO 
is considered a BCS class IV drug, the application of f2 
could be useful to completely characterize and compare 
dissolution profiles. In this sense, considering that both 
samples B and E, as well as the reference product D, are 
‘very rapidly dissolving’ formulations, the mathematical 
evaluation is considered not necessary because the 
profiles would be essentially similar (13–17). In the case 
of samples A and C, f2 was calculated prior to verification 
that all requirements for its application were fulfilled (13–
17). In the comparison of sample A with the reference 
formulation, the obtained f2 results were 45.4, 46.8, 
and 44.0 for buffer pH 1.2, 4.5, and 6.8, respectively. In 
the case of comparison of sample C with the reference 
product D, the results were 33.6, 34.4, and 36.9, 
respectively. All obtained similarity factors were lower 
than the limit value of 50, suggesting that these profiles 
could not be considered similar, which is in accordance 
with the ANOVA results (13–17). 
Medium A B C D (Ref.) E




















pH 6.8 79.7 ± 
2.6*







All evaluated products fulfilled Argentinean 
Pharmacopeial specifications  for  critical quality attributes 
Results are expressed in % of labelled amount dissolved (mean ± SD).
* indicates significant differences (p ≤ 0.05) detected, with respect to the 
reference formulation D.
Table 4. Dissolution Efficiency Results for Allopurinol Formulations
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under the experimental conditions employed. These 
results demonstrate that the 300-mg ALLO products 
tested  from the local market are pharmaceutical 
equivalents. Nevertheless, caution must be critically 
exerted, especially with products A and C, considering 
that patients may interchange multisource products 
for economic reasons, regardless of biopharmaceutical 
performance. 
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